Here’s whether AstraZeneca PLC (AZN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bearish.
🔴
Bearish
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.39% over 10 days); 3-month momentum negative (-11.2%). Currently 22.0% off its 52-week high. Score: -5/7.
AZN is trading below its 200-day MA ($184.30) — a key warning sign the longer-term trend is under pressure. An RSI of 65.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +3.1% compares to +20.5% for SPY (trailed the market by 17.3%). The current 22.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $10,314 today
vs. S&P 500 (SPY) — same period trailed market by 17.3%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($184.30)
✗Above 50-day MA ($172.15)
✓RSI(14) neutral zone (30–70) — currently 65.8
✓Positive return (+3.1%)
!Within 10% of period high (−22.0%)
Period Range $165.98
$145.79$212.71
RSI (14) 65.8
0 · OversoldOverbought · 100
Key Metrics
Price$165.98
Period Return+3.1%
Period High$212.71
Period Low$145.79
Drawdown−22.0%
MA-50$172.15
MA-200$184.30
RSI (14)65.8
Avg Volume (30d)3.9M
vs. SPYtrailed by 17.3%
Return Rank#550 of 999
Trend Signals
Price is below the 200-day moving average ($184.30)
Price is below the 50-day moving average ($172.15)